Eiger BioPharmaceuticals, Inc. along with its affiliates, filed a motion for joint administration of their Chapter 11 bankruptcy cases in the US Bankruptcy Court on April 1, 2024. As per the motion, the debtor seeks the joint administration of the cases of its affiliates, Ebpi Merger, Inc., Eiger Biopharmaceuticals Europe Limited, Eigerbio Europe Limited, and Eb Pharma, LLC, with its own case for administrative and procedural purposes. Eiger BioPharmaceuticals, Inc. has been proposed as the lead debtor.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.32 USD | -13.11% | -42.00% | -65.55% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-65.55% | 3.95M | |
+2.42% | 42.75B | |
+47.70% | 41.61B | |
+12.04% | 41.34B | |
-8.83% | 26.59B | |
+7.04% | 25.49B | |
-22.60% | 18.12B | |
+30.39% | 12.24B | |
-2.06% | 11.76B | |
+9.06% | 11B |
- Stock Market
- Equities
- EIGR Stock
- News Eiger BioPharmaceuticals, Inc.
- Motion for Joint Administration Filed by Eiger BioPharmaceuticals, Inc.